Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global Cancer Statistics, 2012. CA a Cancer J. Clin. 2015;652:87–108. DOI:10.3322/caac.21262.
   PubMed Web of Science ®Google Scholar
• Storm HH, Kejs AMT, Engholm G, Tryggvadóttir L, Klint A, Bray F, Hakulinen T. Trends in the overall survival of cancer patients diagnosed 1964-2003 in the Nordic countries followed up to the end of 2006: the importance of case-mix. Acta Oncol. 2010;495:713–724. DOI:10.3109/0284186X.2010.484426.
   PubMed Web of Science ®Google Scholar
• Herzog TJ, Pothuri B. Ovarian cancer: a focus on management of recurrent disease. Nat Clin Pr. Oncol. 2006;311:604–611. DOI:10.1038/ncponc0637.
   PubMedGoogle Scholar
• Coleman RL, Monk BJ, Sood AK, Herzog TJ. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat. Rev. Clin. Oncol. 2013;104:211–224. DOI:10.1038/nrclinonc.2013.5.
   PubMed Web of Science ®Google Scholar
• Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 2003;3483:203–213. DOI:10.1056/NEJMoa020177.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Sci (80-.). 2015;3486230:62–68. DOI:10.1126/science.aaa4967.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using t-cell transfer immunotherapy. Clin. Cancer Res. 2011;1713:4550–4557. DOI:10.1158/1078-0432.CCR-11-0116.
   PubMed Web of Science ®Google Scholar
• Andersen R, Donia M, Ellebaek E, Borch TH, Kongsted P, Hendel HW. Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-in fi ltrating lymphocytes and an attenuated IL2 regimen. Clin. Cancer Res. 2016;1–12. DOI:10.1158/1078-0432.CCR-15-1879.
   Web of Science ®Google Scholar
• Besser MJ, Shapira-Frommer R, Itzhaki O, Treves AJ, Zippel DB, Levy D, Kubi A, Shoshani N, Zikich D, Ohayon Y, et al. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin. Cancer Res. 2013;1917:4792–4800. DOI:10.1158/1078-0432.CCR-13-0380.
   PubMed Web of Science ®Google Scholar
• Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Chacon J, Wu R, Lizee G, Mahoney S, Glass M, Johnson VE, et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 2012;1824:6758–6770. DOI:10.1158/1078-0432.CCR-12-1177.Specific.
   PubMed Web of Science ®Google Scholar
• Pilon-Thomas S, Kuhn L, Ellwanger S, Janssen W, Royster E, Marzban S, Kudchadkar R, Zager J, Gibney G, Sondak VK, et al. Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J. Immunother. 2012;358:615–620. DOI:10.1097/CJI.0b013e31826e8f5f.
   PubMed Web of Science ®Google Scholar
• Stevanović S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR, Dudley ME, Yang JC, Sherry RM, Kammula US, et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J. Clin. Oncol. 2015;3314:1543–1550. DOI:10.1200/JCO.2014.58.9093.
   PubMed Web of Science ®Google Scholar
• Tran E, Turcotte S, Gros A, Robbins PF, Lu Y, Dudley ME, Parkhurst MR, Yang JC. Rosenberg S a. cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Sci (80-.). 2014;9May:641–645. DOI:10.1126/science.1251102.
   Google Scholar
• Freedman RS, Edwards CL, Kavanagh JJ, Kudelka AP, Katz RL, Carrasco CH, Atkinson EN, Scott W, Tomasovic B, Templin S. Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial. J. Immunother. Emphasis Tumor Immunol. 1994;163:198–210. DOI:10.1097/00002371-199410000-00004.
   PubMed Web of Science ®Google Scholar
• Aoki Y, Takakuwa K, Kodama S, Cancer EO, Tanaka K, Takahashi M, Tokunaga A. Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer. Cancer Res 1991;51:1934–1939.
   Google Scholar
• Westergaard MCW, Andersen R, Kjeldsen JW, Hasselager T, Lajer H, Donia M. Preclinical development of tumor-infiltrating lymphocytes (TILs) based adoptive cell transfer immunotherapy (ACT) for patients with advanced ovarian cancer. Ann. Oncol. 2016;27Suppl_8: DOI:10.1093/annonc/mdw141.
   Google Scholar
• Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory t cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 2004;221:745–763. DOI:10.1146/annurev.immunol.22.012703.104702.
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Suzanne L, Restifo NP, Royal RE, Kammula U, White DE, Sharon A, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 2005;2310:2346–2357. DOI:10.1200/JCO.2005.00.240.
   PubMed Web of Science ®Google Scholar
• Robbins PF, Kassim SH, Tran TLN, Crystal JS, Morgan RA, Feldman SA, Yang JC, Dudley ME, Wunderlich JR, Sherry RM, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T cell receptor: long term follow up and correlates with response. Clin. Cancer Res. 2015;215:1019–1027. DOI:10.1161/CIRCRESAHA.116.303790.
   PubMed Web of Science ®Google Scholar
• Secondino S, Zecca M, Licitra L, Gurrado A, Schiavetto I, Bossi P, Locati L, Schiavo R, Basso S, Baldanti F, et al. T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results. Ann. Oncol. 2012;232:435–441. DOI:10.1093/annonc/mdr134.
   PubMed Web of Science ®Google Scholar
• Mcguire WP, Hoskins WJ, Brady MF, Kugera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 1996;3341:1–6. DOI:10.1056/NEJM199606133342404.
   PubMed Web of Science ®Google Scholar
• Piccart M, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000;929:699–708.
   PubMed Web of Science ®Google Scholar
• Kavanagh J, Stringer A, Copeland L, Gershenson D, Phase PS. II Trial of Fludarabine in Patients With Epithelial Ovarian Cancer. Cancer Treat. Rep. 1986;703:425–426.
   PubMedGoogle Scholar
• Von Hoff D, Kronmal R, O’Toole R, Surwit E, Hutton J, Phase AD. II study of fludarabine phosphate (NSC-312887) in patients with advanced ovarian cancer. Am J Clin Oncol. 1988;112:146–148. DOI:10.1097/00000421-198804000-00011.
   PubMed Web of Science ®Google Scholar
• Burrell RA, Swanton C. Tumour heterogeneity and the evolution of polyclonal drug resistance. Mol. Oncol. 2014;86:1095–1111. DOI:10.1016/j.molonc.2014.06.005.
   PubMed Web of Science ®Google Scholar
• Lawrence M, Stojanov P, Polak P, Kryukov G, Cibulskis K, Sivachenko A, Carter S, Stewart C, Mermel C, Roberts S, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;4997457:214–218. DOI:10.1038/nature12213.Mutational.
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;391:1–10. DOI:10.1016/j.immuni.2013.07.012.
   PubMed Web of Science ®Google Scholar
• Pennock GK, Chow LQM. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. Oncologist. 2015;207:812–822. DOI:10.1634/theoncologist.2014-0422.
   PubMed Web of Science ®Google Scholar
• Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 2013;7312:3591–3603. DOI:10.1158/0008-5472.CAN-12-4100.
   PubMed Web of Science ®Google Scholar
• Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, M V S, Davis T, Henry-Spires R, MacRae S, Willman A, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Pnas. 2003;1008:4712–4717. DOI:10.1073/pnas.0830997100.
   PubMed Web of Science ®Google Scholar
• Hodi FS, Butler M, Oble DA, Seiden MV, Fg H, Kruse A, Macrae S, Nelson M, Canning C, Lowy I, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc. Natl. Acad. Sci. U. S. A. 2008;1058:3005–3010. DOI:10.1073/pnas.0712237105.
   PubMed Web of Science ®Google Scholar
• Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A. Safety and Antitumor Activity of Anti – PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. J Clin Oncol. 2016;3334:11–13. DOI:10.1200/JCO.2015.62.3397.
   Google Scholar
• Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, Eppolito C, Qian F, Lele S, Shrikant P, et al. Tumor-infiltrating NY-ESO-1–specific CD8 + T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc. Natl. Acad. Sci. 2010;10717:7875–7880. DOI:10.1073/pnas.1003345107.
   PubMed Web of Science ®Google Scholar
• Ellebaek E, Iversen TZ, Junker N, Donia M, Engell-Noerregaard L, Met O, Hölmich LR, Andersen RS, Hadrup SR, Andersen MH, et al. Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. J. Transl. Med. 2012;101:169. DOI:10.1186/1479-5876-10-169.
   PubMed Web of Science ®Google Scholar
• Keilholz U, Goey SH, Punt CJ, Proebstle TM, Salzmann R, Scheibenbogen C, Schadendorf D, Liénard D, Enk A, Dummer R, et al. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the european organization for research and treatment of cancer melanoma cooperative group. J. Clin. Oncol. 1997;157:2579–2588. DOI:10.1200/JCO.1997.15.7.2579.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, Lh S, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer. 2009;452:228–247. DOI:10.1016/j.ejca.2008.10.026.
   PubMed Web of Science ®Google Scholar
• Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J. Nucl. Med. 2009;50Suppl 1:122S–50S. DOI:10.2967/jnumed.108.057307.
   PubMed Web of Science ®Google Scholar
• Engell-Noerregaard L, Hendel HW, Johannesen HH, Alslev L, Svane IM. FDG PET scans as evaluation of clinical response to dendritic cell vaccination in patients with malignant melanoma. Cancer Immunol. Immunother. 2013;621:17–25. DOI:10.1007/s00262-012-1306-5.
   PubMed Web of Science ®Google Scholar
• Donia M, Larsen SM, Met O, Svane IM. Simplified protocol for clinical-grade tumor-infiltrating lymphocyte manufacturing with use of the Wave bioreactor. Cytotherapy. 2014;168:1117–1120. DOI:10.1016/j.jcyt.2014.02.004.
   PubMed Web of Science ®Google Scholar
• Tran KQ, Zhou J, Durflinger KH, Langhan MM, Shelton TE, Wunderlich JR, Robbins PF, Rosenberg SA, Dudley ME. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J. Immunother. 2008;318:742–751. DOI:10.1097/CJI.0b013e31818403d5.
   PubMed Web of Science ®Google Scholar